Is pseudocatalase established vitiligo care?
The current British guideline reviewed by SteadySkin does not establish pseudocatalase as standard vitiligo care. That does not prove that every past or future formulation is ineffective; it means pseudocatalase is not established treatment right now. Evidence Evidence Evidence
What is known
- Sources cited, not yet graded
Two controlled evaluations of a pseudocatalase preparation alongside narrowband UVB have been read and registered here. Neither found clear added benefit. The 2009 double-blinded, placebo-controlled trial found no statistically significant advantage when both groups received narrowband UVB. The 2002 open single-centre evaluation found no clear benefit, and reported skin reactions. The guideline evaluates established management choices and evidence limits. SteadySkin has not completed an exact-full-text review that supports a product-specific efficacy claim. We do not summarize one from an abstract, seller page, or testimonial.
What is uncertain
- Depends on you
Neither study was established as commercially independent in this review, and neither proves every preparation ineffective. Products sharing the name may differ. The name alone does not establish that a current product matches a studied preparation, has reliable manufacturing, or produces a clinical benefit. Whether a product like this belongs anywhere in your care is a question for a dermatologist who can see your skin and your current plan.
Questions for your clinician or the seller
What exact product and formulation are you proposing?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Where is the full-text evidence for this exact product?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Is this established care, a compounded product, or research?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What if the claim also involves ultraviolet light?
Do not turn a pseudocatalase claim into a self-directed ultraviolet plan. Narrowband UVB remains clinician-directed care. A cream or seller claim does not establish a safe device, schedule, application sequence, or monitoring plan. Evidence Evidence
What is known
- Sources cited, not yet graded
Current phototherapy guidance separates clinician-directed medical treatment from unsupervised ultraviolet exposure and requires condition-specific precautions and oversight.
What is uncertain
- Depends on you
Without exact full-text and product review, SteadySkin cannot establish whether a seller’s combined claim matches any studied intervention or how it should affect an individual plan.
Questions for your clinician or the seller
Who is clinically responsible for the entire plan?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What exact evidence supports combining this product with ultraviolet treatment?
Saving keeps this on your device and needs JavaScript, which is off in this browser.How do the device instructions and clinical precautions apply?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence and update context
This optional layer shows the evidence boundary I reviewed as of 2026-09-15.
- What this evidence supports
- Two controlled evaluations of a pseudocatalase preparation alongside narrowband UVB have been read and registered here. Neither found clear added benefit. The 2009 double-blinded, placebo-controlled trial found no statistically significant advantage when both groups received narrowband UVB. The 2002 open single-centre evaluation found no clear benefit, and reported skin reactions. The guideline evaluates established management choices and evidence limits. SteadySkin has not completed an exact-full-text review that supports a product-specific efficacy claim. We do not summarize one from an abstract, seller page, or testimonial.
- What it does not establish
- Neither study was established as commercially independent in this review, and neither proves every preparation ineffective. Products sharing the name may differ. The name alone does not establish that a current product matches a studied preparation, has reliable manufacturing, or produces a clinical benefit. Whether a product like this belongs anywhere in your care is a question for a dermatologist who can see your skin and your current plan.
Pending clinical review
This statement has a dated source and is waiting for a clinician's sign-off.
Applicability check
Who was studied?
These fields show what the cited evidence reports about the people and body sites behind outcome or safety claims. “Not reported” means the reviewed source omitted the field; “Pending exact source review” means SteadySkin has not made that determination yet.
Do not turn a pseudocatalase claim into a self-directed ultraviolet plan. Narrowband UVB remains clinician-directed care. A cream or seller claim does not establish a safe device, schedule, application sequence, or monitoring plan.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a safety claim, but exact population extraction is still pending. It cannot publish or support an estimate of individual risk until that review is complete.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- Clinical and Experimental Dermatology (Patel DC, et al.)Observational study · Supporting research, tier 3Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that this uncontrolled single-center evaluation did not find clear evidence of benefit for the studied pseudocatalase-and-light approach and reported skin reactions.
What it does not support
Funding independence was not established in this review, and the design cannot establish comparative efficacy, evaluate current marketed products or authorize unsupervised use.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Bakis-Petsoglou S, et al.)Randomized trial · Clinical research, tier 2Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that this small controlled trial found no statistically significant added benefit from its pseudocatalase preparation when both groups received narrowband ultraviolet B.
What it does not support
Funding independence was not established in this review; the trial does not prove every preparation ineffective, establish equivalence of marketed products or support self-directed light use.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Eleftheriadou V, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence. Its classification table defines mucosal vitiligo as the oral or genital mucosae. One mucosal site alone is filed as undetermined or unclassified. Its differential diagnosis table lists genital or extragenital lichen sclerosus among the conditions that can be mistaken for vitiligo. That table also lists eczema, psoriasis, lichen planus, pityriasis alba and piebaldism. It calls autoimmunity a contributor to the pathogenesis of vitiligo. It reports an earlier review finding a possible negative impact on intimacy and sexual functioning. It tells clinicians to discuss the psychosocial impact of living with the condition. R28 offers a skin camouflage visit to people who want one. R10 to R14 name potent or very potent topical steroids as the first choice, with a topical calcineurin-inhibitor cream as an option for the face. These are different creams with different proof behind them. R20 names narrowband UVB as the first light option. It says the skin often does better on the face and trunk than on hands and feet. It says there is not enough proof to use any one current pill alone for vitiligo that is not changing. R25 and Table 2 keep cell grafting for vitiligo that is not changing and did not respond to other care. They also say a doctor cannot always tell if the vitiligo has truly stopped changing.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage. Its differential diagnosis table is a list, not a method a reader can apply to their own skin. It does not say how to tell any two of those conditions apart. It gives no figure for how often vitiligo affects genital skin.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Goulden V, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
It supports that traditional NB-UVB fluorescent lamps emit a narrow UVB band peaking around 311 nanometres. It backs wearing UV-protective goggles and keeping UV scatter off people nearby. It records the consent form naming goggles and the same clothing at each session. It also covers clinical uses, how it compares with other light treatments, safety limits including sunburn-type reactions, and the added safeguards home phototherapy needs.
What it does not support
It does not provide a personal treatment plan, approve a particular home setup, or replace the instructions for your own device. SteadySkin never reproduces its treatment schedules.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.